ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice

Wagdi Almishri1,2‡, Liam A. Swain2‡, Charlotte D’Mello2, Tyson S. Le2, Stefan J. Urbanski3 and Henry H. Nguyen1,4*†

1 Department of Microbiology, Immunology, and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2 Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3 Department of Pathology & Laboratory Medicine, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4 Division of Gastroenterology and Hepatology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) is a ubiquitously expressed membrane-bound enzyme that mediates shedding of a wide variety of important regulators in inflammation including cytokines and adhesion molecules. Hepatic expression of numerous cytokines and adhesion molecules are increased in cholestatic liver diseases including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), however, the pathophysiological role of ADAM17 in regulating these conditions remains unknown. Therefore, we evaluated the role of ADAM17 in a mouse model of cholestatic liver injury due to bile duct ligation (BDL). We found that BDL enhanced hepatic ADAM17 protein expression, paralleled by increased ADAM17 bioactivity. Moreover, inhibition of ADAM17 activity with the specific inhibitor DPC 333 significantly improved both biochemical and histological evidence of liver damage in BDL mice. Patients with cholestatic liver disease commonly experience adverse behavioral symptoms, termed sickness behaviors. Similarly, BDL in mice induces reproducible sickness behavior development, driven by the upregulated expression of cytokines and adhesion molecules that are in turn regulated by ADAM17 activity. Indeed, inhibition of ADAM17 activity significantly ameliorated BDL-associated sickness behavior development. In translational studies, we evaluated changes in ADAM17 protein expression in liver biopsies obtained from patients with PBC and PSC, compared to normal control livers. PSC and PBC patients demonstrated increased hepatic ADAM17 expression in hepatocytes, cholangiocytes and in association with liver-infiltrating immune cells compared to normal controls. In summary, cholestatic liver injury in mice and humans is associated with increased hepatic ADAM17 expression. Furthermore, inhibition of ADAM17 activity improves both cholestatic liver injury and associated sickness behavior development, suggesting that ADAM17 inhibition may represent a novel therapeutic approach for treating patients with PBC/PSC.

Keywords: ADAM17 (a disintegrin and metalloprotease 17), TACE (TNF-α converting enzyme), cholestasis, autoimmune liver disease, inflammation, sickness behavior, therapeutic
INTRODUCTION

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) is type 1 transmembrane metalloprotease with wide tissue expression in the body, that facilitates the cleavage and release of a variety of substrates involved in both the initiation and propagation of inflammation (1). In addition, ADAM17 is also expressed on the cell surface of various innate and adaptive immune cell populations (e.g. monocytes/macrophages, T lymphocytes, neutrophils) (2, 3). ADAM17 regulates the cleavage and release of over 80 different substrates including cytokines, cytokine receptors, growth factors, cell transport proteins, and various enzymes (1, 4). In the context of inflammation, ADAM17 cleaves and releases the cytokines IL-6 (and IL-6 receptor), tumor necrosis factor (TNF) α, and various adhesion molecules including ICAM-1 and VCAM-1, which critically regulate the development of numerous disease processes including sepsis, inflammatory bowel disease, psoriasis and multiple sclerosis (5–12). This broad role played by ADAM17 in the initiation and propagation of inflammation has made the development of ADAM17 inhibitors an appealing target for treating numerous chronic inflammatory and autoimmune conditions. Indeed, a number of ADAM17 inhibitors are in various stages of development for potential clinical use (1, 2, 13).

Enhanced ADAM17 activity has been shown to augment hepatic inflammation in animal models. Specifically, mice lacking TIMP3, the endogenous inhibitor of ADAM17, exhibit increased liver ADAM17 activity that is associated with increased proinflammatory cytokine production, hepatocyte necrosis, and hepatic leukocyte infiltration (14). In the setting of cholestatic liver disease, both progressive liver damage and impaired liver regeneration have been attributed, in part, to the differential hepatic expression of the proinflammatory cytokines TNF-α and IL-6; the processing and subsequent biological effects of which are mediated by ADAM17 (15–18). Increased circulating TNFα levels have been documented in both patients with cholestatic liver diseases, and in animal models of cholestasis (19–21). Polymorphisms in the TNFα gene, resulting in increased production of this cytokine, have been linked to the development of primary biliary cholangitis (PBC) (22). Increased hepatic TNFα levels have also been identified in patients with primary sclerosing cholangitis (PSC) (23). These findings suggest that ADAM17 activity, which critically regulates downstream soluble TNFα production, may be increased in cholestatic liver diseases. Interestingly, the hepatoprotective effects of ursodeoxycholic acid (UDCA), the keystone therapy in PBC, has been attributed in part to its inhibitory effect on mature ADAM17 formation (24).

PBC and PSC patients commonly experience a variety of comorbid psychological manifestations (i.e., fatigue, depression, anxiety, social withdrawal), also termed sickness behaviors, that lead to detrimental patient quality of life and an increased burden of disease (25–27). UDCA is the current mainstay of treatment for cholestatic liver diseases, including PBC. However, although it prevents disease progression in PBC patients, UDCA treatment does not typically improve disease-associated behavioral symptoms (28). This highlights an unmet medical need for new treatment approaches to beneficially impact these symptoms (collectively termed sickness behaviors). Interestingly, sickness behaviors experienced in cholestatic patients can be readily modeled in animal models of cholestatic liver disease including BDL mice (29, 30), and are characterized by increased immobility and a reduced propensity to engage in social interactions. Although the specific mechanisms leading to the development of sickness behaviors in cholestatic liver disease are not yet fully understood, alterations in pro-inflammatory cytokine production (including TNFα and IL-6), cellular adhesion molecule expression on cerebral endothelial cells, production of the chemokine monocyte chemoattractant protein-1 (MCP-1) by brain microglia, and cerebral recruitment of inflammatory monocytes have been broadly implicated (31–33). Moreover, a recent study showed that the ADAM17–mediated release of soluble TNFα enhanced endothelial cell expression of both adhesion molecules and MCP-1, with inhibition of ADAM17 preventing monocyte adhesion to endothelium (8). Current findings therefore suggest that ADAM17 may regulate the initiation/progression of liver injury in cholestatic liver disease, as well as the development of cholestatic liver disease-associated sickness behavior development.

The broad biological impact of liver disease-related increase in ADAM17 expression and activity could therefore make inhibition of ADAM17 activity a potential novel target for treating both cholestasis associated liver injury and sickness behavior development. Therefore, we evaluated the hepatic expression/activity of ADAM17, and the impact of ADAM17 inhibition, on liver injury and sickness behavior development in a well characterized murine model of cholestasis. To evaluate for potential applicability of our findings in the clinical setting, we characterized cholestatic liver disease-related changes in ADAM17 protein expression in liver biopsies obtained from patients with PBC and PSC.

METHODS AND MATERIALS

Animal Model of Cholestatic Liver Disease Due to Bile Duct Ligation (BDL)

Male C57BL/6 mice 8-10 weeks of age (Jackson Labs, Bar Harbor, Maine) were housed in a light controlled room at 22°C with a 12-hour day/night cycle and free access to water and food. All animals were treated humanely under the University of Calgary Animal Care Committee guidelines, and all experiments were performed in accordance with the guidelines of the Canadian Council on Animal Care. The University of Calgary Animal Care Committee prospectively approved the animal research prior to study initiation. Cholestasis was induced via bile duct ligation and resection (BDL), which is a well characterized and widely used model of cholestatic liver injury (16, 34). Sham resection consisted of laparotomy with bile duct manipulation without ligation or resection. All surgeries were performed under isoflurane with efforts made to minimize animal suffering.
Studies were performed at 10 days post-surgery, a time when mice are overtly cholestatic (34). Animals were sacrificed on day 10 using inhaled isoflurane and subsequent studies were carried out as outlined in the methodology section below. Necrotic areas within the liver of BDL vs sham mice were quantified using ImageJ software (35) in H&E stained liver sections, and the percentage of necrotic vs normal liver tissue area calculated using the formula: ([number of total pixels of necrotic areas/total number of pixels of entire liver section] x 100) (36). The severity of liver injury and degree of bile duct proliferation were also evaluated by a single expert liver histopathologist blinded to treatment groups (S.U.) (30). The degree of bile duct proliferation was assessed using a subjective scoring system by the blinded histopathologist (S.U.). A score of 0 (no bile duct proliferation) to 3 (marked bile duct proliferation) was utilized. In addition, serum alanine aminotransferase (ALT) and total bilirubin levels were measured using standard techniques (Calgary Laboratory Services, Calgary, Alberta).

**Determination of BDL-Induced Changes in Hepatic ADAM17 Protein Expression and Enzymatic Activity**

(a) Hepatic ADAM17 protein expression: Liver samples from day 10 BDL and sham control mice were obtained as described above, placed in 5% formalin, and embedded in paraffin. Samples were sectioned 5 µm thick and antigen retrieval performed by incubating samples in 1X citric acid for 20 minutes at 80°C. Endogenous peroxidase was blocked with 3% hydrogen peroxide. Slides were then blocked with 4% goat serum. Rabbit monoclonal anti-ADAM17 antibody (10µg/ml; LifeSpan Biosciences; Seattle WA) was applied at 4°C overnight, followed by biotinylated goat anti-rabbit IgG (10µg/ml; 90 minutes room temperature) along with avidin biotin complex (Vectastain Elite ABC; Burlingame, CA) and Nova Red peroxidase substrate (Vector Labs; Burlingame CA). Positive ADAM17 protein expression was indicated by red staining.

(b) Hepatic ADAM17 enzymatic activity determination: ADAM17 activity was measured in liver homogenates obtained from sham and BDL mice using a commercially available fluorometric ADAM17 Activity Assay Kit (Anaspec, Freemont, CA) (37). Briefly, under inhalational anesthesia, mouse livers were flushed with cold Phosphate Buffered Saline (PBS), surgically removed, and weighed. Livers were then homogenized with assay buffer containing Triton-X 100 and incubated for 15 minutes at 4°C. Samples were then centrifuged at 2000xg and supernatants collected. 96-well plates were prepared as per the manufacturer’s protocol, including appropriate controls (sample alone, buffers alone, ADAM17 substrate alone, and 20 µM ADAM17 inhibition compound containing TAPI-O). A reference standard was also prepared on the same plate for ADAM17 activity quantification purposes. Endpoint fluorometric intensity readings were obtained one-hour post-incubation (Fluostar Optima; BMG Labtech, Durham, NC); with excitation and emission wavelengths at 490 nM and 520 nM, respectively. Fluorometric activity was normalized per mg of protein, and ADAM17 activity expressed as relative units reflecting only the proportion of ADAM17 activity inhibited by the specific ADAM17 inhibitor, TAPI-O.

**Isolation and Flow Cytometric Phenotyping of Hepatic Immune Cells From BDL and Sham Mice**

Livers from cholestatic and control mice at day 10 were perfused with 20 mL of ice-cold PBS. Immune cell isolation was carried out as previously described (38, 39). In brief, mechanical dissection of whole livers was completed by passing tissue through a 70µm filter using the blunt end of a syringe with 10% RPMI + fetal bovine serum. Immune cells were isolated utilizing density gradient centrifugation overlaying 37% over top of 70% Percoll®. Immune cells were labelled with fluorescent tagged antibodies, and immunophenotyping of isolated hepatic immune cells expressing ADAM17 in BDL and sham mice assessed using multicolor flow cytometry. For cell surface staining, cell isolates were first treated with Fc receptor blocker (2.0 µg/tube; CD16/CD32; 93; ebioscience, San Diego, CA) prior to staining. Predominant immune cell types observed in our human samples guided immunophenotyping in cholestatic mice. Hepatic T lymphocytes were identified using anti-mouse CD3e (0.25 µg/tube;145-2C11; ebioscience, San Diego, CA), and monocytes/macrophages identified by co-labeling cells with anti-mouse CD11b (0.125 µg/tube; M1/70; ebioscience, San Diego, CA) and LY6C (0.25 µg/tube; H1K1.4; ebioscience, San Diego, CA). ADAM17 expression was determined using anti-mouse ADAM17 Alexa Fluor 647 (0.5 µg/tube; ab150115; Abcam, Toronto, Canada). Cell populations of interest were acquired using the Attune™ Acoustic Focusing Cytometer (Applied Biosystems; Burlington ON). Data was analyzed using FlowJo® software (Treestar, Ashland OR). Gating was carried out as follows: Live cells were gated, and dead cells were excluded. Using forward scatter (FSC) and side scatter (SSC) regions coinciding to cells of interest were included. Fluorescence-minus-one (FMO) controls were used for the accurate designation of cells with fluorescence above background levels (38). Appropriate isotype controls were used to determine the specificity of all antibodies used for flow cytometry. Cell numbers were calculated based on the percentage of cells found in the gate of interest and the total cell numbers isolated from each liver.

**Impact of ADAM17 Inhibition on Liver Injury and Sickness Behavior Development in Cholestatic Mice**

(i) Impact of ADAM17 inhibition on BDL-associated liver damage: Selective ADAM17 inhibitors have been developed for possible clinical application (2, 40). DPC 333 is a well characterized selective ADAM17 inhibitor, with potent oral and parenteral bioactivity in rodents and humans (also called BMS 561392; kind gift of Bristol-Myers-Squibb Canada) (13). We confirmed the effectiveness of ADAM17 inhibition by DPC 333 in preliminary pilot studies. To do this, mice were treated with DPC 333 (10 mg/kg, ip) or vehicle (n=2 mice/group) 30 minutes prior to ip endotoxin administration (1 mg/kg; O111:B4;
Sigma), and 2 hours later serum TNFα levels were measured using a LumineX® assay (Eve Technologies, Calgary, Canada). DPC 333 reduced endotoxin-induced elevations in serum TNFα levels by greater than 50% (data not shown). Therefore, in subsequent studies, BDL mice were treated with either DPC 333 (10 mg/kg ip twice daily; dose previously shown to effectively inhibit ADAM17 activity in mice) (13) or saline vehicle, starting at day 1 post-BDL surgery and continuing until day 10 post-BDL surgery, at which time mice were sacrificed. Livers were then removed for H&E staining (for histological quantification of liver damage) and blood samples taken for biochemical assessment of liver injury (i.e. serum ALT and total bilirubin levels). Hepatic necrotic areas were quantified using Image J software as described above. Evaluations were also performed by an expert, blinded liver histopathologist (S.U.).

(ii) Effects of ADAM17 inhibition on BDL-associated sickness behavior development: Sickness behavior development in mice was assessed using the social exploration/investigation paradigm. Using this paradigm, we have previously shown that BDL mice reproducibly develop sickness behaviors which are readily quantified (34, 41). Briefly, prior to testing, test mice were housed in individual cages for a period of 24 hours. Experiments were performed between 7:00 and 10:00 am on Day 10 post-surgery. A 3–4 week old juvenile male C57BL/6 mouse was introduced into the home cage of the test mouse, and social investigative behavior assessed for a period of 10 minutes by two blinded observers (30, 34, 41). Two aspects of social exploratory behavior were quantified: (i) total time the test mouse spent engaging in social investigative behavior, and (ii) the total time the test mouse remained immobile after the introduction of the juvenile mouse into the test cage. DPC 333 or vehicle treated BDL mice were assessed on day 10 post-surgery for the development of sickness behaviors using this social investigation paradigm.

Cholestatic Liver Disease-Associated Alterations in Hepatic ADAM17 Protein Expression in PBC and PSC Patients
Hepatic ADAM17 protein expression was evaluated in percutaneous liver biopsy samples obtained from patients (University of Calgary ethics protocol number E-23683) with the cholestatic liver diseases primary biliary cholangitis [PBC; n=3] and primary sclerosing cholangitis [PSC; n=3]. PBC/PSC liver sections were compared to biopsies from normal liver (n=3). Patients had all been assessed by a hepatologist within the University of Calgary Liver Unit, and other aetiologies of chronic liver diseases ruled out. The diagnosis of PBC and PSC were all confirmed with liver biopsies in these patients. Antigen retrieval was performed using 1 X citric acid at 80°C for 20 minutes. Primary staining was done using a monoclonal rabbit anti-ADAM17 antibody (10µg/mL overnight at 4°C; LifeSpan Biosciences; Seattle WA), followed by goat anti-rabbit IgG along with Avidin Biotin Complex and Nova Red peroxidase substrate staining (Vector Labs, Burlingame CA). Sections were counterstained with Hematoxylin. Appropriate staining controls were employed to ensure antibody specificity.

Immune Cell ADAM17 Expression in Hepatic Inflammatory Cell Infiltrates in PBC and PSC Patients
Immunostaining of PSC/PBC patient liver biopsy samples for T lymphocytes used anti-CD3 (1:100 dilution; Thermo Fisher) as a pan-T cell marker, using standardized protocols (Calgary Laboratory Services, Calgary, Canada). Immune cell ADAM17 expression was determined as follows: Antigen retrieval was performed using 1x citric acid at 80°C for 20 minutes. Slides were blocked with 4% goat and 4% donkey serum in PBS. Primary staining was done using a monoclonal rabbit anti-ADAM17 antibody (10µg/mL; LifeSpan Biosciences; Seattle WA) in combination with (i) T cell subset markers, identified with mouse anti-human CD8a (AMC908; eBioscience; San Diego, CA) or mouse anti-human CD4 (N1UG0; eBioscience; San Diego, CA), or (ii) monocytes/macrophages, identified with mouse anti-human CD68 (815CU17; eBioscience; San Diego, CA) at 4°C overnight. Secondary antibody staining was done using both goat anti-rabbit IgG Alexa Fluor 488 and Donkey anti-mouse IgG Alexa Fluor 647 (90 minutes at room temperature). Nuclei were stained using DAPI, as per manufacturer protocol (ThermoFisher Scientific; Eugene, OR). Liver immunofluorescent microscopy was performed using a multiphoton confocal microscope (Nikon A1 MP+ multiphoton confocal microscope; Melville NY). Excitation laser wavelengths of 402.5 nm and 639.7 nm were used for the identification of ADAM17 and immune cell markers (CD4/CD8/CD68), respectively.

Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). Data were analyzed using GraphPad Instat software. For comparison between two means, Student’s unpaired t-test was used. For multiple comparisons, one-way ANOVA followed by Student-Neuman-Keuls post hoc test was used. p < 0.05 was considered significant.

RESULTS
Hepatic ADAM17 Activity and Expression Is Increased in BDL Mice
Consistent with previous findings, BDL mice developed overt liver injury and cholestasis as reflected by significant increases in serum bilirubin and ALT levels vs sham control mice (ALT: sham 12.1 ± 2.2 U/L vs BDL 754.0 ± 77.8 U/L; p<0.02; total bilirubin: sham 9.2 ± 8.2 µmol/L vs BDL 262.0 ± 29.6 µmol/L; p<0.05; n=4-6 mice/group). ADAM17 protein expression was increased in liver tissue from BDL vs sham mice as seen on immunohistochemistry (Figure 1A). Consistent with this observation, ADAM17 enzymatic activity was also significantly increased in liver homogenates in BDL vs sham mice (Figure 1A). Increased hepatic ADAM17 protein expression was identified in hepatocytes, cholangiocytes and immune cells which had infiltrated the liver (Figure 1A). To further characterize the ADAM17 expressing infiltrating immune cells, hepatic immune cells were isolated and evaluated with flow cytometry. A significant increase in the total numbers of
Increased hepatic ADAM17 activity and protein expression in cholestatic mice. Diagram of experimental design. Bile duct ligation (dotted line) with resection in between ligatures was performed in BDL mice. Mice were overtly cholestatic 10 days post surgery at which point liver histology, liver immune cell isolation, liver TACE activity, serum biochemistry and behavioral studies were performed. (A) Qualitative hepatic ADAM17 protein expression in liver tissue from day 10 BDL and sham mice. Representative images illustrating positive ADAM17 staining (red colour) being mainly localized to hepatocytes (perforated arrows), cholangiocytes (black arrows), and immune cells within inflammatory infiltrates (white arrows). ADAM17 protein expression was also detected in sham liver, however the increased ADAM17 expression was more readily observed in BDL livers. Images acquired at 20X and are representative of similar findings in n = 7 BDL and n = 5 sham mice. Quantitative hepatic ADAM17 enzymatic activity (expressed as Relative Fluorescent Units/µg of total liver protein). The mean ± SEM was from n = 7 BDL and n = 5 Sham mice; *p < 0.05. These experiments were repeated twice with similar results. (B) Increased ADAM17 expression in hepatic tissue derived immune cells. Flow cytometry histogram and absolute cell count of ADAM17+ expression in monocytes and T lymphocytes isolated from day 10 BDL and sham livers. Absolute cell counts are represented as mean ± SEM for data from n = 4-6 BDL and n = 4-5 sham mice; *p < 0.05. This experiment was repeated twice with similar results.
ADAM17 expressing monocytes and T lymphocytes were documented in BDL vs sham mice (Figure 1B). No differences in mean fluorescence intensity (MFI) for ADAM17 expression were found in any of the immune cell populations in either experimental group (data not shown).

**In Vivo Inhibition of ADAM17 Activity With DPC 333 Leads to an Improvement in Liver Biochemistry, Histological Liver Damage, and Attenuates Sickness Behavior Development in BDL Mice**

(i) Reduction of liver injury in BDL mice with ADAM17 inhibition: Inhibition of ADAM17 activity with DPC 333 administration resulted in a significant decrease in serum ALT levels in BDL mice (Figure 2A), but not serum bilirubin levels (Figure 2A), compared to the vehicle-treated BDL group. Paralleling improvements in serum ALT levels, DPC 333 treatment in BDL mice significantly attenuated liver damage, shown histologically as a significant reduction in hepatic necrosis (Figure 2B). Quantification of total liver necrotic area (expressed as % necrotic area) demonstrated a significant reduction in hepatic necrosis in DPC 333 treated BDL mice, vs vehicle treated BDL mice (3.0 ± 1.0% vs 11.0 ± 2.2% respectively; p<0.05; n=7 mice in BDL+DPC 333 group and n=6 mice in BDL + vehicle group). A significant reduction in cholangiocyte proliferation (CK19+Ki67+ cells), a histological feature commonly encountered in cholestatic liver injury (Figure 2C), was also documented in DPC 333-treated BDL mice. The findings of reduction in liver injury severity with DPC 333 treatment was also confirmed by our liver histopathologist (S.U) blinded to treatment group who counted total number of hepatic necrotic areas per liver section in DPC 333 treated vs vehicle treated BDL mice. (DPC 333 treated 14.7 ± 4.1 vs. vehicle treated 30.2 ± 5.3; p<0.05; n=6 BDL + DPC 333 mice and n=4 BDL + vehicle mice) (Figure 2B). In addition, DPC 333 treatment also resulted in a reduction in a subjective score of bile duct proliferation in DPC 333 treated vs vehicle treated BDL mice, as estimated by our blinded histopathologist (Score from 0 to 3: Score = 1.3 ± 0.2 for DPC 333 treated and Score = 2.3 ± 0.3 for vehicle treated; p<0.05; n=6 BDL + DPC 333 mice and n=4 in BDL + vehicle mice). The impact of ADAM17 inhibition on liver fibrosis development in response to BDL surgery was assessed via Sirius red staining of liver sections to detect collagen deposition. BDL mice showed increased Sirius red staining compared to sham controls. However, ADAM17 inhibition in BDL mice by DPC 333 treatment did not alter the development of hepatic fibrosis (Figure 3A).

(ii) ADAM17 inhibition attenuates sickness behavior development in BDL mice: BDL mice develop overt sickness behaviors, as reflected by a decrease in time spent engaging in social investigation and an increase in time remaining immobile (30, 34, 41). ADAM17 inhibition with DPC 333 treatment resulted in a significant reduction in sickness behavior development in BDL mice compared to vehicle-treated BDL mice, manifested as a significant increase in the time DPC 333-treated BDL mice spent engaging in social investigating behavior, and a decrease in time they spent remaining immobile, compared to vehicle treated BDL mice (Figure 3B).

**Enhanced Hepatic ADAM17 Protein Expression in the Cholestatic Liver Diseases PBC and PSC**

Given the findings of ADAM17 inhibition attenuating liver injury and sickness behavior in BDL mice, we were interested in evaluating ADAM17 in patients diagnosed with chronic autoimmune cholestatic liver disease. We noted ADAM17 protein expression was strikingly increased in liver biopsy samples obtained from patients with both PBC and PSC compared to normal controls (Figure 4). In both PBC and PSC patients, ADAM17 protein expression (red stain) was readily noted in hepatocytes (most notably in areas of the liver adjacent to active inflammation), and in areas of hepatic immune cell infiltration. When immune cell rich areas within the livers of PBC and PSC patient were characterized by immunohistochemistry, T lymphocytes (CD3+) were found to be the predominant cell type present (Figure 4B). To address this in more detail we next evaluated the different hepatic immune cell populations of PBC and PSC patients for ADAM17 expression; specifically CD4+ T cells, CD8+ T cells, and monocytes/macrophages (CD68+ cells) which are known to express ADAM17 (42, 43). In normal liver samples there was no portal area inflammatory cell infiltration evident (data not shown). In PBC and PSC livers, ADAM17 expressing CD68+ (i.e., monocyte/macrophage) immune cells were noted in hepatic portal inflammatory cell infiltrates (PBC; Figure 4C; top row, and PSC; Figure 4C; bottom row associated with classic concentrically fibrosed duct). However, ADAM17 expressing CD68+ cells were less abundant than were ADAM17 expressing T-cells in inflamed portal areas in PBC and PSC livers. CD68 positive staining immune cells were also observed within hepatic sinusoids, and these cells were morphologically consistent with Kupffer cells (not shown). Evaluation of ADAM17 expressing T cells in liver sections from both PBC (Figure 4E) and PSC (Figure 4D) patients demonstrated that portal T cell inflammatory infiltrates were significantly enriched in both CD4+ and CD8+ ADAM17-expressing T cell subsets. Moreover, ADAM17+ T cells were also observed directly infiltrating the biliary epithelium (Figure 4E).

**DISCUSSION**

The role of ADAM17 in regulating inflammation relates to its ability to process various substrates, including proinflammatory cytokines (e.g. TNFα), cytokine receptors (e.g. TNFRI/TNFRII, IL-6Rα), adhesion molecules (L-selectin, VCAM-1, ICAM-1) and growth factors (e.g. EGFR ligands) (2–4, 40). Increased tissue ADAM17 expression has been reported in different immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriasis and inflammatory bowel disease highlighting its role in mediating downstream injury/inflammation (6–8). This has made ADAM17 inhibition an attractive and potential upstream therapeutic target for these various conditions (2, 4, 40, 44, 45). Although a number of
studies have highlighted ADAM17 activity as an important regulator of liver injury and repair (14, 46–48), the role of ADAM17 in the context of cholestatic liver disease is poorly understood. We have identified enhanced hepatic expression and enzymatic activity of ADAM17 in a mouse model of cholestatic liver injury. Moreover, cholestatic liver injury severity in this model as reflected biochemically by serum ALT levels and histopathologically by liver damage scores and bile duct proliferation (49), was attenuated by treatment with the specific ADAM17 inhibitor DPC 333. Of note, DPC 333 treatment did not impact the BDL-associated increase in serum bilirubin levels, which is not surprising given that in this model the common bile duct is surgically completely blocked. Interestingly, ADAM17 inhibition did not attenuate liver fibrosis development in BDL mice, possibly reflected by the relatively modest fibrotic response in day 10 BDL mice. Therefore, murine models employing hepatic toxic agents such as dimethylnitrosamine, diethylnitrosamine, and carbon tetrachloride over a longer duration of time may be more effective in mimicking human liver fibrosis.

FIGURE 2 | Inhibition of ADAM17 enzymatic activity attenuates liver injury in BDL mice. Diagram of experimental design depicting bile duct ligation (dotted line) with resection in between ligatures in BDL mice. Twice daily treatment with DPC 333 (10 mg/kg) was provided via intraperitoneal injection. Mice were overtly cholestatic 10 days post surgery at which point experimentation was completed. (A) Improvement in serum ALT levels (but not total bilirubin levels) in DPC 333-treated BDL vs vehicle-treated BDL mice (mean ± SEM of data from n = 7 DPC 333 treated BDL mice and n = 7 vehicle treated BDL mice; *p < 0.05). (B) Representative H&E stained liver sections showing reduction in areas of liver cell necrosis (thick black arrows) in DPC 333-treated vs vehicle-treated BDL mice. Images are 20X and are representative of n = 7 DPC 333 treated group and n = 6 vehicle treated group. Bar graph shows counting of necrotic areas by blinded liver pathologist (DPC 333 treated 14.7 ± 4.1 vs. vehicle treated 30.2 ± 5.3; p < 0.05; n = 6 BDL + DPC 333 mice and n = 4 BDL + vehicle mice). (C) Attenuation of bile duct proliferation in BDL mice with DPC 333 treatment vs vehicle (PBS). Representative immunohistochemistry of BDL livers with and without DPC 333 showing CK19 (green), Ki67 (red) and nuclear staining (blue). Bar graph quantification done in a blinded manner with significant reduction in Ki67+ cholangiocytes in BDL mice treated with DPC-333 vs vehicle (PBS); *p < 0.033; n=3 and 4 mice/group.
appropriate to study the role of ADAM17 in liver fibrosis and cirrhosis development (50).

Our group has previously defined critical roles for the ADAM17-regulated cytokines TNFα and IL-6, cytokine receptor TNFRI, and immune cell adhesion molecule VCAM-1, in cholestasis associated sickness behavior development in BDL mice (29, 34, 41, 51). Additionally, our group (30, 52) and others (53) have previously shown that the BDL model is associated with elevated circulating serum IL-6 and TNFα levels along with the reproducible development of liver injury and associated sickness behaviors. Interestingly, both serum IL-6 and TNF-α levels have been reported to be linked with PBC and PSC disease process (54–56). In our current study, we now show that inhibition of ADAM17 ameliorates cholestasis-associated sickness behavior development, as reflected by an increase in time spent engaging in social interaction and a decrease in time spent remaining immobile in DPC 333-treated cholestatic mice. Patients with cholestatic liver disease (e.g. PBC and PSC) commonly experience a number of extrahepatic symptoms including fatigue, malaise and loss of social interest. These symptoms have been collectively called sickness behaviors, and by definition must originate by changes occurring within the brain (29, 57). Importantly, these symptoms often represent a significant societal and personal burden for cholestatic patients, and are strongly associated with detriments in patient health-related quality of life (57, 58). However, symptom severity in cholestatic patients correlates poorly with disease severity, and symptoms are typically not altered significantly by currently available therapies (i.e. UDCA in PBC patients) (59, 60). The peripheral signaling pathways that link the diseased liver to the brain in cholestatic patients, to give rise to these disease-associated sickness behaviors, are not well understood (29). Our demonstration that ADAM17 inhibition attenuates sickness behavior development in our model highlights a potential novel therapeutic avenue for treating these
FIGURE 4 | (A) Increased ADAM17 protein expression in PBC and PSC livers: Representative immunohistochemical images (20X) showing increased hepatic ADAM17 protein expression in patients with Primary Biliary Cholangitis (PBC; middle panel) and Primary Sclerosing Cholangitis (PSC; bottom panel) compared to normal liver (top panel). Images are representative of similar findings in n = 3 liver samples/group. For all three panels grey arrows indicate hepatocytes, white arrows indicate inflammatory infiltrate, and solid black arrows indicate cholangiocytes. Relative to normal liver, ADAM17 protein expression (red staining) is markedly increased in PBC and PSC. (B) Portal inflammatory infiltrates in PBC and PSC are mainly composed of T lymphocytes: CD3+ T cells within immune cell infiltrates in inflamed portal areas of liver biopsies from patients with PBC (Top Panel) and PSC (Bottom Panel). Images acquired at 20X and are representative of similar findings in n = 3 patients/group. Positive staining is indicated by amber/brown color. (C) Expression of ADAM17 (green colour) on the cell surface of CD68+ monocytes/macrophages (red colour) in PBC and PSC liver samples. Nuclei are stained blue. Images are representative of similar findings in n = 3 patients/group. ADAM17+ CD68+ cells were readily identified within inflammatory cell infiltrates within portal areas (white circle in PBC sample). Interestingly, in PSC liver sections only, ADAM17+CD68+ monocytes could also be identified infiltrating between bile duct (BD) cholangiocytes (denoted by white arrow). (D) ADAM17 (green colour) expression on CD4+ and CD8+ T lymphocyte subsets (red colour) in liver biopsies from patients with PSC. Nuclei are stained blue. Images are representative of similar findings in n = 3 patients. ADAM17 expression by both CD4+ and CD8+ T cells was readily noted within inflammatory infiltrates (denoted by white highlight) within expanded portal areas in PSC livers. Increased ADAM17 expression was also noted in hepatocytes (not shown) and biliary epithelium/cholangiocytes. (E) ADAM17 (green colour) expression on CD4+ (top panels) and CD8+ (bottom panels) T lymphocyte subsets (red colour) in liver biopsies from patients with PBC. Nuclei are stained blue. Images are representative of similar findings in n = 3 PBC patients. ADAM17 expression by both CD4+ and CD8+ T cells was readily identified within inflammatory infiltrates (denoted white line) within expanded portal areas in PBC livers. Increased ADAM17 expression was also noted in hepatocytes and biliary epithelium/cholangiocytes. All images are representative of other patient PBC and PSC samples. Experiments were repeated total 2 times with similar results.
symptoms in cholestatic patients, which are currently very challenging to manage in the clinic.

Given our current findings that ADAM17 plays an important role in regulating liver injury and sickness behavior development in BDL mice, we next delineated changes in hepatic ADAM17 expression in the setting of two important cholestatic liver diseases in patients: PBC and PSC. Indeed, similar to our observations in BDL mice, we found that both PBC and PSC were associated with an increase in hepatocyte ADAM17 protein expression which was most evident in hepatocytes identified as being closest to areas of active liver inflammation and parenchymal destruction. Given that ADAM17 has numerous targets important for regulating inflammation, increased ADAM17 expression in these areas likely contributes to a concerted change in the parenchymal and immune landscape within the local inflammatory milieu. Specifically, the ADAM17-mediated enhanced release of proinflammatory cytokines within the liver microenvironment, such as cleaving soluble TNFα from the cell surface of infiltrating or resident hepatic immune cell populations (44), likely significantly contributes to liver injury and has been implicated in the pathogenesis of both PBC and PSC (19, 21, 61, 62). The TNFα receptor TNFRI is richly expressed on the hepatocyte cell surface, and activation of membrane expressed TNFRI by TNFα can induce hepatocyte apoptosis (63, 64). Moreover, hepatocytes themselves may contribute to the inflammatory milieu in the liver environment. Others have shown using a conditional knockout of ADAM17 in hepatocytes can attenuate liver injury and systemic proinflammatory signaling in endotoxin treated mice (47). The broad role of ADAM17 inhibition on liver injury can also be seen in studies linking ADAM17 activity and hepatic stellate cell signaling in the setting of liver fibrosis in NASH (65) and ADAM17 in overall NAFLD development (66). However, targeting ADAM17 to produce an overall beneficial effect during inflammation may also depend on the context and cause of injury within the liver environment. Contrary to what we have shown here, others report increased ADAM17 activity being protective through its TNFRI shedding, which reduces overall TNFRI available to bind TNFα on the hepatocyte surface. These ADAM17-mediated protective effects were observed in experimental in vitro endotoxin-induced liver injury (67), and in vivo ischemia/reperfusion injury in rats (68). These differential findings from those in our study may be due to limitations of the in vitro assays, animal models utilized, and potentially mechanistic differences in underlying drivers of liver injury; endotoxin and ischemia primarily affecting hepatic vasculature in contrast to BDL-related liver injury that is driven by cholestasis and hepatic retention of mediators normally secreted in bile. Given this, the proinflammatory role of ADAM17 may be unique to certain etiologies of liver injury and warrants further investigation. Future studies evaluating the role of ADAM17 in other forms of liver disease including viral infection, autoimmune hepatitis, and drug induced liver injury may shed more light into this context dependent role of ADAM17 in liver health.

Cholangiocytes are target cells in both PBC and PSC, with bile duct damage and proliferation commonly observed in both of these human diseases. Similarly, bile duct proliferation has also been described in murine BDL models (69). We identified increased ADAM17 protein expression in cholangiocytes in liver biopsies obtained from PBC and PSC patients, compared to normal liver tissue. Moreover, we found similar enhanced cholangiocyte ADAM17 expression in BDL mice. Others have observed that cholangiocytes can regulate inflammatory responses within the liver (70, 71). One such mechanism includes signaling through the epidermal growth factor receptor (EGFR) expressed on cholangiocytes, which can be activated by several ligands, including transforming growth factor α (TGFα). The activation of EGFR in this fashion is important for stimulating cholangiocyte proliferation and repair processes. ADAM17-mediated secretion of TGFα may therefore have important implications for the regulation of bile duct inflammation, proliferation, and destruction in cholestatic diseases; a suggestion that is supported by our current findings of reduced bile duct proliferation in DPC 333-treated BDL mice. Interestingly, we also observed ADAM17 expressing immune cells infiltrating bile duct epithelium in both PBC and PSC patients, a process that may further alter cholangiocyte function, signaling, and responses to cholestasis. Further studies are required to better characterize the role of ADAM17 within the liver microenvironment and inflammatory milieu as it pertains to cholangiocyte response, bile duct injury, TGFα, EGFR signaling and overall cholestasis.

Expression of ADAM17 on the immune cell surface may also be an important regulator of tissue immune responses within the liver through the release of cell surface proteins involved in inflammatory processes, including cytokines (TNFα), their receptors (TNFRI, TNFRII, IL-6Rα), and adhesion molecules (L-selectin, VCAM-1) (5, 7, 10–12). We found that immune cell infiltrates in PBC and PSC patient livers were predominately T cells; an observation consistent with previous reports (72, 73). Moreover, within these hepatic T cell inflammatory infiltrates in PBC/PSC patients we readily identified both ADAM17+ CD4 and CD8 T cells. Consistent with our current findings, ADAM17 expression has previously been identified at low levels on human CD4 T cell surface membranes, and are transiently mobilized to the cell surface membrane during cell activation, ultimately regulating the release of soluble IL-6Rα (74) and enhancing FasL processing (75, 76), both effects having the potential to drive tissue injury and inflammation. In contrast, others have reported effector CD8 T cell activation during influenza infection resulting in ADAM17-mediated TNFRII cleavage and release from the cell surface membrane. Soluble TNFRII released in this manner critically regulates influenza-related pulmonary inflammation by binding to and inhibiting the proinflammatory effects of soluble TNFα released within the lung (77). In our study, we observed an amelioration of both BDL-associated liver injury and sickness behavior development with DPC 333-mediated ADAM17 inhibition, suggesting that in the setting of cholestatic liver injury, ADAM17 plays a more proinflammatory role. In addition to lymphocytes, ADAM17 is also expressed on the cell surface of macrophages and monocytes and is an important regulator of proinflammatory cytokine and cytokine receptor release from these cells during inflammation. For example, ADAM17 is the major ‘sheddase’ for both TNFα and TNFRI/
TNFRII from activated macrophages (78). In liver biopsies from
PBC and PSC patients, we readily identified ADAM17” CD68”
macrophages/monocytes. Similar to our findings in the livers of
PBC/PSC patients, we also identified significant increases in both
ADAM17” T cells and monocytes within the livers of BDL mice
using flow cytometry. The relative contribution made by hepatic
infiltration of ADAM17” immune cells in the regulation of the
overall inflammatory response within the liver environment
remains unclear. A potential role for both myeloid- and
lymphocyte-associated ADAM17 regulation of liver damage have
been previously reported. Specifically, deletion of ADAM17 in
myeloid cells completely prevented carbon tetrachloride-induced
acute hepatitis, and attenuated endotoxin-induced elevations in
circulating TNFα levels (47). The duality of ADAM17 to
seemingly regulate both pro- and anti-inflammatory outcomes
reflects the importance of understanding the context in which
ADAM17 functions. Heterogeneity in terms of the site of end
organ injury, agent/model of organ injury, and the subsequent
predominant immune cell compartment(s) involved in driving
injury, may all contribute to differing reports of the role
ADAM17 plays in various inflammatory conditions. Our study
identifies increased ADAM17 expression and activity as a
proinflammatory driver of liver injury and sickness behavior
development in a murine model of cholestaticis, and also shows
that ADAM17 expression is similarly enhanced in the liver of PBC
and PSC patients in close proximity to areas of portal inflammatory
cell infiltration, inflammation and hepatocyte injury. Therefore, our
findings are consistent with ADAM17 playing a predominant
proinflammatory role in the cholestatic liver environment.

There are limitations in our study that warrant further
discussion. The BDL model does lead to measurable fibrosis on
day 10 post surgery (79); however, chronic cholestasis and chronic
fibrosis do not develop within this limited time period. In our
hands, mice kept over the 10 day period post BDL surgery can lose
more than 20% of their body weight, which meets our defined
humane endpoint, making the study of chronic cholestasis difficult
with the BDL model. Despite these model limitations, the BDL
model have reproducible hepatic inflammatory environments
representative of cholestasis (i.e., cholangiocyte injury, ductular
reaction, portal inflammation and acute fibrosis), and associated
sickness behaviours. Future studies could investigate the role of
ADAM17 regulation in the context of chronic cholestasis in Mdr2
or Atp8b1 (80, 81) mutant mice. Evaluating ADAM17 in these
models would better capture the role of ADAM17 inhibition in the
context of longer term cholestatic liver injury. These genetic
strains themselves have limitations however, as these specific
mutations are not universally present in PBC/PSC patients and
are more likely representative of genetic cholestatic liver disease in
humans such as progressive familial intrahepatic cholestasis.
Furthermore, we utilized only one selective ADAM17 inhibitor
(i.e., DPC 333) in this study. The advent of oral small molecule
therapy is altering the therapeutic landscape of chronic
inflammatory conditions (82). TMI-005 is an oral small
molecule inhibitor of ADAM17 and has been studied in various
inflammatory conditions including Rheumatoid Arthritis (83).
The use of TMI-005 could be considered in future studies to
broaden the generalizability of our findings of ADAM17
inhibition in cholestasis. However, it is important to note that
TMI-005 has inhibitory activity that extends beyond ADAM17 to
include Matrix Metalloproteinase (MMP) 1 and 13. Whether
concurrent inhibition of MMP-1 and MMP-13 can act
synergistically with ADAM17 remains uncharacterized in
cholestatic liver disease. Overall, our study highlights the role
and potential for targeting ADAM17 in cholestatic liver injury.

In summary, hepatic ADAM17 expression and activity are
enhanced in the setting of the cholestatic liver injury, and
ADAM17 inhibition significantly attenuates liver damage and
sickness behavior development in cholestatic mice. Moreover,
enhanced ADAM17 expression in PBC/PSC patient biopsy
samples was associated with hepatocytes, cholangiocytes, and was
most evident in inflamed portal areas and in areas of parenchymal
injury and immune cell infiltration. As such, ADAM17 inhibition
may represent a novel therapeutic approach for patients with PBC
and PSC, treating both disease-associated liver damage and adverse
behavioral symptoms. Moreover, given the current lack of effective
therapeutic options for treating PSC, inhibition of ADAM17
activity may represent a new approach for the treatment of this
progressive and devastating disease.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and
approved by Conjoint Health Research Ethics Board Research
Services Office University of Calgary. The patients/participants
provided their written informed consent to participate in this
study. The animal study was reviewed and approved by Health
Sciences Animal Care Committee (HSACC) University of Calgary.

AUTHOR CONTRIBUTIONS

HN conceived, designed, and performed the experiments. LS,
CDM, TL, and WA planned and performed the experiments.
SU scored human and animal liver samples in a blinded fashion.
HN and LS drafted and edited the manuscript. All authors provided
critical feedback to shape the research, analysis, and final version of
the manuscript.

FUNDING

Funding from Cal Wenzel Family Foundation Chair in Hepatology.

ACKNOWLEDGMENTS

Diagrams in figures were created with BioRender.com.
39. Wondimu Z, Santodomingo-Garzon T, Le T, Swain MG. Proteomic Role of Interleukin-17 in Murine NKT Cell-Driven Acute Experimental Hepatitis. *Am J Pathol* (2010) 177(5):2334–46. doi: 10.2353/ajpath.2010.090028.

40. Arriaga J, Esselens C. ADAM17 as a Therapeutic Target in Multiple Diseases. *Curr Pharm Des* (2015) 20(9):2319–35. doi: 10.2174/13816120978682398.

41. D’Mello C, Le T, Swain MG. Cerebral Microglia Recruit Monocytes Into the Brain in Response to Tumor Necrosis Factoralpha Signaling During Peripheral Organ Inflammation. *J Neurosci Off J Soc Neurosci* (2009) 29(7):2089–102. doi: 10.1523/JNEUROSCI.3657-08.2009.

42. Rovida E, Paccagnini A, Rosso MD, Peschon J. TNF-α-Converting Enzyme Cleaves the Macrophage Colony-Stimulating Factor Receptor in Macrophages Undergoing Activation. *J Immunol* (2001) 166(3):1583–9. doi: 10.4049/jimmunol.166.3.1583.

43. Maltzan Kv, Tan W, Pruett SB. Investigation of the Role of TNF-α Converting Enzyme (TACE) in the Inhibition of Cell Surface and Soluble TNF-α Production by Acute Ethanol Exposure. *PloS One* (2012) 7(2):e29890. doi: 10.1371/journal.pone.0029890.

44. Black RA. Tumor Necrosis Factor-Alpha Converting Enzyme. *Int J Biochem Cell Biol* (2002) 34(1):1–5. doi: 10.1016/s1357-7257(01)00097-8.

45. Liu S, D’Amore M, Sisto M. ADAM17 at the Interface Between Inflammation and Autoimmunity. *Immunol Lett* (2014) 162(1):159–69. doi: 10.1016/j.imlet.2014.08.008.

46. Sharma M, Mohapatra J, Malik U, Wagh A, Singh A, Patel HM, et al. Selective Inhibition of Tumor Necrosis Factor-α Converting Enzyme Attenuates Liver Toxicity in a Murine Model of Concanavalin A Induced Auto-Immune Hepatitis. *Int Immunopharmacol* (2013) 17(2):229–36. doi: 10.1016/j.intimp.2013.06.014.

47. McMahan RS, Riehle KJ, Fausto N, Campbell JS. A Disintegrin and Metalloproteinate 17 Regulates TNF and TNFR1 Levels in Inflammation and Liver Regeneration in Mice. *Am J Physiol - Gastrointest Liver Physiol* (2013) 305(1):G25–34. doi: 10.1152/ajpgi.00326.2012.

48. Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, et al. The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. *Clin Liver Dis* (2020) 15(3):110–4. doi: 10.1016/j.cld.2019.07.002.

49. Nezvorova YA, Boyer-Diaz Z, Mello C, Nguyen H, Ajuebor MN, Kubes P, et al. TNF-α-Mediated Liver Congestion and Blunted Microcapsule Formation Are Resistant to Death and Fulminant Liver Injury Induced by Angiostatic Anti-Fas Antibody. *Cell Death Differ* (2003) 10(9):997–1004. doi: 10.1038/sj.cdd.4401281.

50. Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Craia MJ. Tumor Necrosis Factor-Induced Toxic Liver Injury Results From JNK2-Dependent Activation of Caspase-8 and the Mitochondrial Death Pathway. *J Biol Chem* (2006) 281(22):15258–67. doi: 10.1074/jbc.M512953200.

51. Cai B, Dongiovanni P, Corey KE, Wang X, Shmakarov IO, Zheng Z, et al. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. *Cell Metab* (2020) 32(1):406–21. doi: 10.1016/j.cmet.2019.11.013.

52. Casagrande V, Mauriello A, Bischetti S, Mavilio M, Federici M, Menghini R. Hepatocyte Specific TIMP3 Expression Prevents Diet Dependent Fatty Liver Disease and Hepatocellular Carcinoma. *Sci Rep* (2017) 7(1):1–2. doi: 10.1038/s41598-017-09633-w.

53. Chanthaphavong RS, Loughran PA, Lee TYS, Scott MJ, Billiar TR. A Role for cGMP in INOS-Induced TACE/ADAM17 Activation, Translocation, and TNFR1 Shedding in Hepatocytes. *J Biol Chem* (2012) 287(43):35887–98. doi: 10.1074/jbc.M112.365171.

54. Tang Z-Y, Loss G, Carmody I, Cohen AJ. TIMP-3 Ameliorates Hepatic Ischemia/Reperfusion Injury Through Inhibition of Tumor Necrosis Factor-Alpha-Converting Enzyme Activity in Rats. *Transplantation* (2006) 82(11):1518–23. doi: 10.1097/01.tp.0000243381.41777.c7.

55. Bai H, Zhang N, Xu Y, Chen Q, Khan M, Potter JJ, et al. Yes-Associated Protein Regulates the Hepatic Response After Bile Duct Ligation. *Hepatology* (2012) 56(3):1097–107. doi: 10.1002/hep.25769.

56. Pinto C, Giordano DM, Maroni L, Marzioni M. Role of Inflammation and Proinflammatory Cytokines in Cholangiocyte Pathophysiology. *Biochim Biophys Acta* (2017) 1864(4):1270–8. doi: 10.1016/j.bbadis.2017.07.024.

57. Isse K, Harada K, Nakamura Y. IL-8 Expression by Biliary Epithelial Cells Is Associated With Neutrophil Infiltration and Reactive Bile Ductules. *Liver Int Off J Int Assoc Study Liver* (2007) 27(5):672–80. doi: 10.1111/j.1478-3231.2007.01465.x.

58. Hoheneser S, Oude-Eferink RPJ, Beuers U. Primary Biliary Cirrhosis. *Semin Immunopathol* (2009) 31(3):283–307. doi: 10.1007/s00281-009-0164-5.

59. Jones DEJ. The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. *Clin Liver Dis* (2020) 15(3):110–4. doi: 10.1016/j.cld.2019.07.002.

60. Ebsen H, Lettau M, Kabelitz D, Janssen O. Subcellular Localization and Activation of ADAM Proteases in the Context of Fas Mediated T Lymphocyte Inactivation. *Mol Immunol* (2015) 65(2):416–28. doi: 10.1016/j.molimm.2015.02.008.

61. Ebsen H, Schröder A, Kabelitz D, Janssen O. Differential Surface Expression of ADAM10 and ADAM17 on Human T Lymphocytes and Tumor Cells. *PloS One* (2013) 8(10):e76853. doi: 10.1371/journal.pone.0076853.

62. DeBerger MP, Ely KH, Wright PF, Thorp EB, Enelow RI. Shedding of TNFα Receptors 1 and 2 Are Resistant to Death and Fulminant Liver Injury Induced by Angiostatic Anti-Fas Antibody. *Cell Death Differ* (2003) 10(9):997–1004. doi: 10.1038/sj.cdd.4401281.
81. Langedijk J, Bolier R, Tolenaars D, Ten Bloemendaal L, Duijst S, de Waart D, et al. Reduced Spontaneous Itch in Mouse Models of Cholestasis. Sci Rep (2021) 11(1):1–3. doi: 10.1038/s41598-021-85660-1

82. Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase Inhibition in Autoimmunity and Inflammation. Nat Rev Drug Discov (2021) 20(1):39–63. doi: 10.1038/s41573-020-0082-8

83. Thabet MM, Huizinga TW. Drug Evaluation: Apratastat, a Novel TACE/MMP Inhibitor for Rheumatoid Arthritis. Curr Opin Invest Drugs (London England: 2000) (2006) 7(11):1014–9.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.